Newly-appointed board of Fortis Healthcare, which is in the process of finding an investor, has again deferred approval of quarterly and annual financial results for the period ended March 31, 2018, saying the issue requires more deliberation.
The board, which met on June 25 for considering results, will reconvene on Tuesday.
"This is to inform that the Board of Directors of the company held a meeting on June 25, 2018, for considering the standalone and consolidated annual accounts for 2017-18 along with the financial results for the quarter and period ended March 31, 2018.
"The members of the board deliberated upon the same and had a detailed discussion with the management, legal advisors and the statutory auditors," Fortis said in a regulatory filing.
It further said in view of the ongoing discussions on the annual accounts, which requires further deliberation, the board decided to adjourn the meeting to be reconvened today.
Fortis said the board meeting commenced at 1600 hours on June 25 and was adjourned at 0215 hours on June 26.
On June 11, Fortis board deferred approval of quarterly and annual financial results to June 25 saying more time was needed to consider the aspects of outcome of an internal investigation on alleged financial irregularities.
On May 30 as well, the board had deferred approval of the results to June 11 citing ongoing deliberations of the conclusions arising from the internal investigation.
The healthcare chain, which is in the process of finding a buyer, had appointed a law firm in March to investigate allegations of fund diversion from Fortis by former promoters Singh brothers.
Markets regulator Sebi is also investigating the matter related to alleged lapses at Fortis and Religare Enterprises. Apart from Sebi, the Serious Fraud Investigation Office (SFIO) has also initiated a probe into the alleged financial irregularities at the two companies.
The probes were initiated against the backdrop of reports that Fortis promoters Malvinder Singh and Shivinder Singh took at least USD 78 million out of the company without any board approval about a year ago.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)